Q-omics provides the consensus-scored RPS29P21 profile across patient tissues and cancer cell-line models. RPS29P21 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS29P21 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, RPS29P21 RNA expression shows 8,473 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, CHOL, and LSCC as cancer lineages where RPS29P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P21 survival associations across molecular data types. RPS29P21 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P21 RNA expression–survival associations across cancer types. High RPS29P21 expression shows unfavorable associations in THCA, ACC, UVM, DLBC, KIRC and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPS29P21 RNA expression.
This table summarizes RPS29P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P21 shows higher tumor expression in CHOL, BRCA, COAD, HNSC and LIHC. The CHOL box plot shows higher RPS29P21 RNA expression in tumor versus normal tissue (log2 FC = +0.510, t-test p < 0.001).
This table shows molecular features associated with RPS29P21 in patient tissues and cancer cell lines. In patient samples, RPS29P21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
